The Radiation and Medical Technology Group Eckert & Ziegler Announces Drastic Dividend Cut for 2023 to Secure Financial Resources for Growth and Expansion in the Radiopharmaceuticals Sector. Despite a Net Profit of 26.3 Million Euros, the Company Plans to Pay Out Only 5 Cents per Share – a Move Far Below Market Expectations of 50 Cents and Which Initially Caused Surprise Among Shareholders.

The decision to nearly completely cut the dividend is justified as a strategic measure to finance new high-yield projects in the growing market for radiopharmaceuticals. The planned projects particularly include the expansion of production capacities. Eckert & Ziegler also intends to achieve greater financial independence from external financing through the dividend cut.

Eckert & Ziegler Aims for Further Revenue Growth in 2024, with Forecasted Earnings of 265 Million Euros, an Increase of Eleven Percent Over the Previous Year. The EBIT Adjusted for Special Effects from Continuing Operations is Expected to Reach Around 50 Million Euros, Compared to 46.9 Million in 2023.

In addition to the adjusted dividend strategy, Eckert & Ziegler is planning the spin-off of Pentixapharm AG, where shareholders are to receive one Pentixapharm share for every Eckert & Ziegler share. This strategic realignment is intended to enable the company to focus more on its core competencies and to strengthen its leading position as a supplier of radioisotopes for the production of radiopharmaceuticals.

Despite Initial Disappointment in the Market Over the Unexpectedly Low Dividend Proposal, Eckert & Ziegler Shares Recovered During the Day, Reflecting Confidence in the Company's Long-Term Strategy and Growth Potential. Analyst Alexander Galitsa of Hauck & Aufhäuser Investment Banking Views the Dividend Cut as a Precautionary Measure Rather Than a Necessity and Continues to See Significant Price Potential for Eckert & Ziegler Shares.